Showing 5471-5480 of 10820 results for "".
- SkinCeuticals US Taps Christina Fair as New GMhttps://practicaldermatology.com/news/skinceuticals-us-taps-christina-fair-as-new-gm/2457861/Christina (Tina) Fair is the new General Manager at SkinCeuticals US. Tina joins the US team from the SkinCeuticals DMI, where she has been the Vice President of Global Marketing since 2015. During her time in the DMI, Tina led the development o
- BrandMD Launches New Tinted, Physical Sunscreenhttps://practicaldermatology.com/news/brandmd-launches-new-tinted-physical-sunscreen/2457863/BrandMD introduced their newest sunscreen, HA Physical Tint SPF 44. HA Physical Tint SPF 44 is a water-resistant, mineral-based formulation to provide well-rounded coverage against UVA and UVB UV radiation. In addition to its chemical-free active ingredients, the formulation also contains antioxi
- Galderma Enters into Long-term Research Agreement on AD with Icahn School of Medicine at Mount Sinai and Northwestern University Feinberg School of Medicinehttps://practicaldermatology.com/news/galderma-enters-into-long-term-research-agreement-on-ad-with-icahn-school-of-medicine-at-mount-sinai-and-northwestern-university-feinberg-school-of-me/2457865/Galderma has signed a joint research agreement on Atopic Dermatitis (AD) with two leading academic institutions—Icahn School of Medicine at Mount Sinai in New York City, and Northwestern University Feinberg School of Medicine in Chicago. This seven-year collaborative agreement aims to enhan
- Thermi and Sinclair Terminate Collaboration on Silhouette Instalifthttps://practicaldermatology.com/news/thermi-and-sinclair-terminate-collaboration-on-silhouette-instalift/2457866/Thermi, an Almirall S.A. company, and Sinclair Pharma have mutually agreed to terminate their collaboration for the marketing of Silhouette Instalift. Both companies have been working through a join
- SkylineDx and Mayo Clinic To Collaborate on Development of Diagnostic Tests for Melanomahttps://practicaldermatology.com/news/skylinedx-and-mayo-clinic-to-collaborate-on-development-of-diagnostic-tests-for-melanoma/2457903/SkylineDx and Mayo Clinic are working together to develop novel diagnostic tests which will improve clinical decision making for melanoma patients. SkylineDx will help Mayo Clinic to optimize and further develop an algorithm to identify risk factor
- Anti-IL22 Therapy May Represent New Treatment Option for Severe ADhttps://practicaldermatology.com/news/researchers-close-in-on-possible-new-treatment-for-severe-ad/2457913/New research suggests that IL-22/Th22 targeting may offer a novel treatment alternative for patients with severe atopic dermatitis (AD). The findings, which appear in the Journal of the American Academy of Dermatology, provide the first e
- Smart Beauty Devices Take Center Stage at CES 2018https://practicaldermatology.com/news/smart-beauty-devices-take-center-stage-at-ces-2018/2457927/The Computer Electronics Show is known as the see-and-be scene for techies – and beauty products and devices always take center stage. “Shopping for skincare products can be an overwhelming and confusing experience for our consumer because she is uncertain about what her
- Jiangsu Hengrui Medicine and Arcutis Partner for Immune-Mediated Dermatology Therapy Using SHR0302https://practicaldermatology.com/news/jiangsu-hengrui-medicine-and-arcutis-partner-for-immune-mediated-dermatology-therapy-using-shr0302/2457936/Jiangsu Hengrui Medicine Co., Ltd., a fully integrated biopharmaceutical company based in Shanghai, and Arcutis, Inc., a biotechnology company based in Menlo Park, CA, entered into an exclusive option and license agreement for the development and commercialization of topical applications of Hengr
- BridgeBio Pharma Appoints Drs. Sanuj Ravindran and Eric Michael David as CEOs-in-Residence to Lead Dermatology and Gene Therapy Programshttps://practicaldermatology.com/news/bridgebio-pharma-appoints-drs-sanuj-ravindran-and-eric-michael-david-as-ceos-in-residence-to-lead-dermatology-and-gene-therapy-programs/2457942/BridgeBio Pharma, a clinical-stage biopharmaceutical company, today announced that it has strengthened its executive leadership team with two key hires who will join the company as CEOs-in-residence. Sanuj Ravindran, MD, will serve as CEO of PellePharm, Inc. and wil
- SK Breakthrough: FDA Approves Eskata (hydrogen peroxide) Topical Solution from Aclarishttps://practicaldermatology.com/news/sk-breakthrough-fda-approves-eskata-hydrogen-peroxide-topical-solution-from-aclaris/2457950/The FDA has approved ESKATA™ (hydrogen peroxide) topical solution, 40% (w/w) from Aclaris Therapeutics, Inc. for the treatment of seborrheic keratoses (SKs). SKs are non-cancerous skin growths that affect more than 83 million American adults. They may frequently appear in highly visible are